Pilot and Feasibility Projects at our Institution help establish multidisciplinary collaborations between basic and translational scientists, and integrate well within the overall CF Center. The projects described in this component and associated illustrations reinforce central topics pursued by the P30, including CFTR cellular and structural biology, mechanisms underlying CF tissue pathogenesis, and novel therapeutic interventions for the disease. Pilots are intended to provide initial support for innovative directions and stimulate investigators from other areas to lend their expertise to research concerning CF. The P30 Pilot Program has allowed Center leadership to identify and fund promising early stage research. Functions/goals of this Component are identified by the following Specific Aims:
Specific Aim 1 ? Provide research support that will enable eligible investigators to explore the feasibility of innovative concepts. Projects typically last 1-2 years each, are concordant with the overall objectives of the UAB P30, and are intended to result in further grant support from NIH or other funding agencies.
Specific Aim 2. Provide an administrative framework for oversight and review of Pilot and Feasibility Studies. This includes recommendations regarding continuation (or termination) of Pilots to the P30 Internal Advisory Committee, solicitation and review of Pilot applications, record-keeping with regard to grant and manuscript productivity of Pilot PIs, subsequent career events of awardees, and all aspects of program management. During the current funding cycle, the Pilot and Feasibility Component has been successful as judged by the following criteria: 1) funds were well utilized and awards made to investigators meeting eligibility criteria;2) projects were focused on P30 Center scientific priorities;and 3) Pilot and Feasibility studies were productive (e.g. in terms of publications, subsequent independent R01 or other peer-reviewed support, and/or attraction of new investigator into Center-related research).
From a historical standpoint, Pilot resources have assisted several members of the CF Research Base early in their scientific careers. The Pilot mechanism also helped launch careers of investigators who subsequently accepted faculty positions at outside institutions and continue to pursue CF research. At just four years into its first funding cycle, the UAB P30 Pilot Component has already made important contributions to understanding cystic fibrosis disease mechanism and translational research.
| Montoro, Daniel T; Haber, Adam L; Biton, Moshe et al. (2018) A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature 560:319-324 |
| Lutful Kabir, Farruk; Ambalavanan, Namasivayam; Liu, Gang et al. (2018) MicroRNA-145 Antagonism Reverses TGF-? Inhibition of F508del CFTR Correction in Airway Epithelia. Am J Respir Crit Care Med 197:632-643 |
| Shei, Ren-Jay; Peabody, Jacelyn E; Rowe, Steven M (2018) Functional Anatomic Imaging of the Airway Surface. Ann Am Thorac Soc 15:S177-S183 |
| Clancy, John Paul; Cotton, Calvin U; Donaldson, Scott H et al. (2018) CFTR modulator theratyping: Current status, gaps and future directions. J Cyst Fibros : |
| Plyler, Z E; Birket, S E; Schultz, B D et al. (2018) Non-obstructive vas deferens and epididymis loss in cystic fibrosis rats. Mech Dev : |
| Poore, T Spencer; Virella-Lowell, Isabel; Guimbellot, Jennifer S (2018) Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis. Pediatr Pulmonol 53:E21-E23 |
| Heltshe, Sonya L; Rowe, Steven M; Skalland, Michelle et al. (2018) Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement. Am J Respir Crit Care Med 197:1483-1486 |
| Guimbellot, Jennifer; Solomon, George M; Baines, Arthur et al. (2018) Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros : |
| Cho, Do-Yeon; Lim, Dong-Jin; Mackey, Calvin et al. (2018) Preclinical therapeutic efficacy of the ciprofloxacin-eluting sinus stent for Pseudomonas aeruginosa sinusitis. Int Forum Allergy Rhinol 8:482-489 |
| Raju, S Vamsee; Rowe, Steven M (2018) Not simply the lesser of two evils. Am J Physiol Lung Cell Mol Physiol 314:L236-L238 |
Showing the most recent 10 out of 175 publications
